The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Oncogenes


Psychiatry related information on Oncogenes

  • In contrast, infection of embryos with the ras/myc double oncogene virus resulted in 27% of the animals developing rapidly growing and malignant tumors in a great variety of tissues after a median latency period of 2-3 weeks [6].
  • Activation of the ARF-p53 tumor suppressor pathway is one of the cell's major defense mechanisms against cancer induced by oncogenes [7].
  • Despite the excessive enthusiasm of some proponents of this field and the negativism of its critics (Bishop 1983 a, b; Duesberg 1983), it is clear that analytical tools and new information will be of value in further studies on experimental cancer, regardless of whether cellular oncogenes (c-onc genes) have anything to do with human cancer or not [8].
  • In order to define new prognostic factors useful for therapeutic decision-making, we conducted a study on 38 Ewing's sarcoma samples in which c-myc oncogene expression and Ki67 proliferation index were correlated with clinical outcome [9].

High impact information on Oncogenes

  • Structure-function studies provide a molecular understanding of the significance of connexin diversity and demonstrate the unique regulation of connexins by tyrosine kinases and oncogenes [10].
  • Steroid receptor coactivator-3 (SRC-3/AIB1) is an oncogene frequently amplified and overexpressed in breast cancers [11].
  • We provide evidence that these miRNAs are potential novel oncogenes participating in the development of human testicular germ cell tumors by numbing the p53 pathway, thus allowing tumorigenic growth in the presence of wild-type p53 [12].
  • The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1 [13].
  • Thus, Yki is a critical target of the Wts/Lats protein kinase and a potential oncogene [14].

Chemical compound and disease context of Oncogenes


Biological context of Oncogenes


Anatomical context of Oncogenes


Associations of Oncogenes with chemical compounds

  • Transformation by both v-abl and BCR-ABL oncogenes was reduced 5- to 10-fold, whereas transformation by the serine/threonine kinase oncogene v-mos was unaffected [29].
  • One silencer module is bound in vitro by a 75-93 kd protein, termed NeP1; the other can be bound either by the product of the oncogene v-erbA or by the thyroid hormone receptor [30].
  • This maintenance by v-ErbA of a fully active AP-1 complex is correlated with the abrogation by this same oncogene product of the growth-inhibitory response of chicken embryo fibroblasts to retinoic acid treatment [31].
  • Insertion of multiple copies of the hexamer into one central position in the oncogene results in dislocation of the NH2- and COOH-terminal regions in the primary structure, but has no inhibitory effect on focus induction [32].
  • Most notably, by tightly regulating Trp53 knock-down using tetracycline-based systems, we show that cultured mouse fibroblasts can be switched between proliferative and senescent states and that tumors induced by Trp53 suppression and cooperating oncogenes regress upon re-expression of Trp53 [33].

Gene context of Oncogenes

  • However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16 [34].
  • Molecular analyses delineated the amplicon as a 500-kb region from chromosome band 9q34, containing the oncogenes ABL1 and NUP214 (refs. 5,6) [35].
  • We discovered three tumor suppressor/oncogene pathways involved in hTERT repression [36].
  • Because patients with APL can be induced into remission with high dose RA therapy, we propose that the nonliganded PML-RAR protein is a new class of dominant negative oncogene product [37].
  • Stat3 as an oncogene [38].

Analytical, diagnostic and therapeutic context of Oncogenes


  1. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Caron, H., van Sluis, P., van Hoeve, M., de Kraker, J., Bras, J., Slater, R., Mannens, M., Voûte, P.A., Westerveld, A., Versteeg, R. Nat. Genet. (1993) [Pubmed]
  2. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L.A., Cukier, I.H., Collins, C., Gray, J.W., Diebold, J., Demetrick, D.J., Lee, J.M. Nat. Genet. (2002) [Pubmed]
  3. Phosphorylation of tyrosine-416 is not required for the transforming properties and kinase activity of pp60v-src. Snyder, M.A., Bishop, J.M., Colby, W.W., Levinson, A.D. Cell (1983) [Pubmed]
  4. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Wang, D., Liebowitz, D., Kieff, E. Cell (1985) [Pubmed]
  5. Expression of the PDGF-related transforming protein of simian sarcoma virus in E. coli. Devare, S.G., Shatzman, A., Robbins, K.C., Rosenberg, M., Aaronson, S.A. Cell (1984) [Pubmed]
  6. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Compere, S.J., Baldacci, P., Sharpe, A.H., Thompson, T., Land, H., Jaenisch, R. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  7. Role for PP2A in ARF signaling to p53. Moule, M.G., Collins, C.H., McCormick, F., Fried, M. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  8. Onc genes and other new targets for cancer chemotherapy. Busch, H. J. Cancer Res. Clin. Oncol. (1984) [Pubmed]
  9. Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Sollazzo, M.R., Benassi, M.S., Magagnoli, G., Gamberi, G., Molendini, L., Ragazzini, P., Merli, M., Ferrari, C., Balladelli, A., Picci, P. Tumori. (1999) [Pubmed]
  10. Connexins, connexons, and intercellular communication. Goodenough, D.A., Goliger, J.A., Paul, D.L. Annu. Rev. Biochem. (1996) [Pubmed]
  11. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Li, X., Lonard, D.M., Jung, S.Y., Malovannaya, A., Feng, Q., Qin, J., Tsai, S.Y., Tsai, M.J., O'Malley, B.W. Cell (2006) [Pubmed]
  12. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Voorhoeve, P.M., le Sage, C., Schrier, M., Gillis, A.J., Stoop, H., Nagel, R., Liu, Y.P., van Duijse, J., Drost, J., Griekspoor, A., Zlotorynski, E., Yabuta, N., De Vita, G., Nojima, H., Looijenga, L.H., Agami, R. Cell (2006) [Pubmed]
  13. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1. Eldridge, A.G., Loktev, A.V., Hansen, D.V., Verschuren, E.W., Reimann, J.D., Jackson, P.K. Cell (2006) [Pubmed]
  14. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Huang, J., Wu, S., Barrera, J., Matthews, K., Pan, D. Cell (2005) [Pubmed]
  15. Mechanism of met oncogene activation. Park, M., Dean, M., Cooper, C.S., Schmidt, M., O'Brien, S.J., Blair, D.G., Vande Woude, G.F. Cell (1986) [Pubmed]
  16. Modulation of GABAA receptors by tyrosine phosphorylation. Moss, S.J., Gorrie, G.H., Amato, A., Smart, T.G. Nature (1995) [Pubmed]
  17. Effect of cyclophosphamide therapy on oncogene expression in angioimmunoblastic lymphadenopathy. Klinman, D.M., Steinberg, A.D., Mushinski, J.F. Lancet (1986) [Pubmed]
  18. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. Salmeron, A., Ahmad, T.B., Carlile, G.W., Pappin, D., Narsimhan, R.P., Ley, S.C. EMBO J. (1996) [Pubmed]
  19. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Cheng, J.Q., Godwin, A.K., Bellacosa, A., Taguchi, T., Franke, T.F., Hamilton, T.C., Tsichlis, P.N., Testa, J.R. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  20. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M.S., Aizawa, S., Mak, T.W., Taniguchi, T. Cell (1994) [Pubmed]
  21. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Tachibana, M., Takeda, K., Nobukuni, Y., Urabe, K., Long, J.E., Meyers, K.A., Aaronson, S.A., Miki, T. Nat. Genet. (1996) [Pubmed]
  22. Nucleotide sequences of feline retroviral oncogenes (v-fes) provide evidence for a family of tyrosine-specific protein kinase genes. Hampe, A., Laprevotte, I., Galibert, F., Fedele, L.A., Sherr, C.J. Cell (1982) [Pubmed]
  23. The c-Ha-ras oncogene and a tumor promoter activate the polyoma virus enhancer. Wasylyk, C., Imler, J.L., Perez-Mutul, J., Wasylyk, B. Cell (1987) [Pubmed]
  24. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Jimenez, G.S., Nister, M., Stommel, J.M., Beeche, M., Barcarse, E.A., Zhang, X.Q., O'Gorman, S., Wahl, G.M. Nat. Genet. (2000) [Pubmed]
  25. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Grieco, M., Santoro, M., Berlingieri, M.T., Melillo, R.M., Donghi, R., Bongarzone, I., Pierotti, M.A., Della Porta, G., Fusco, A., Vecchio, G. Cell (1990) [Pubmed]
  26. Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Ming, M., Ewen, M.E., Pereira, M.E. Cell (1995) [Pubmed]
  27. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Matsui, Y., Halter, S.A., Holt, J.T., Hogan, B.L., Coffey, R.J. Cell (1990) [Pubmed]
  28. Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Rettenmier, C.W., Roussel, M.F., Quinn, C.O., Kitchingman, G.R., Look, A.T., Sherr, C.J. Cell (1985) [Pubmed]
  29. Dominant negative MYC blocks transformation by ABL oncogenes. Sawyers, C.L., Callahan, W., Witte, O.N. Cell (1992) [Pubmed]
  30. Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site. Baniahmad, A., Steiner, C., Köhne, A.C., Renkawitz, R. Cell (1990) [Pubmed]
  31. A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Desbois, C., Aubert, D., Legrand, C., Pain, B., Samarut, J. Cell (1991) [Pubmed]
  32. Identification of functional regions in the transforming protein of Fujinami sarcoma virus by in-phase insertion mutagenesis. Stone, J.C., Atkinson, T., Smith, M., Pawson, T. Cell (1984) [Pubmed]
  33. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., Lowe, S.W. Nat. Genet. (2005) [Pubmed]
  34. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., Lowe, S.W. Cell (1997) [Pubmed]
  35. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Graux, C., Cools, J., Melotte, C., Quentmeier, H., Ferrando, A., Levine, R., Vermeesch, J.R., Stul, M., Dutta, B., Boeckx, N., Bosly, A., Heimann, P., Uyttebroeck, A., Mentens, N., Somers, R., MacLeod, R.A., Drexler, H.G., Look, A.T., Gilliland, D.G., Michaux, L., Vandenberghe, P., Wlodarska, I., Marynen, P., Hagemeijer, A. Nat. Genet. (2004) [Pubmed]
  36. Multiple tumor suppressor pathways negatively regulate telomerase. Lin, S.Y., Elledge, S.J. Cell (2003) [Pubmed]
  37. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Kakizuka, A., Miller, W.H., Umesono, K., Warrell, R.P., Frankel, S.R., Murty, V.V., Dmitrovsky, E., Evans, R.M. Cell (1991) [Pubmed]
  38. Stat3 as an oncogene. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., Darnell, J.E. Cell (1999) [Pubmed]
  39. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Xin, J.H., Cowie, A., Lachance, P., Hassell, J.A. Genes Dev. (1992) [Pubmed]
  40. Raf-1 antagonizes erythroid differentiation by restraining caspase activation. Kolbus, A., Pilat, S., Husak, Z., Deiner, E.M., Stengl, G., Beug, H., Baccarini, M. J. Exp. Med. (2002) [Pubmed]
  41. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Warrell, R.P., He, L.Z., Richon, V., Calleja, E., Pandolfi, P.P. J. Natl. Cancer Inst. (1998) [Pubmed]
  42. Replacement of lys 622 in the ATP binding domain of P100gag-mil abolishes the in vitro autophosphorylation of the protein and the biological properties of the v-mil oncogene of MH2 virus. Denhez, F., Heimann, B., d'Auriol, L., Graf, T., Coquillaud, M., Coll, J., Galibert, F., Moelling, K., Stehelin, D., Ghysdael, J. EMBO J. (1988) [Pubmed]
  43. Human c-fos oncogene mapped within chromosomal region 14q21----q31. Barker, P.E., Rabin, M., Watson, M., Breg, W.R., Ruddle, F.H., Verma, I.M. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
WikiGenes - Universities